Navigation Links
Inappropriate Initial Antibiotic Treatment May Extend Stays for Patients with Healthcare-Associated Skin Infections

PHILADELPHIA, Oct. 30 /PRNewswire/ -- Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection. Preliminary results from a new study by the Henry Ford Health System evaluated records from patients who acquired SSTIs in hospital and healthcare settings and those who acquired similar infections in the community. Results from the study, which were presented today at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), also shed new light on baseline risk factors that are associated with inappropriate initial therapy (Abstract #053). This information may help guide clinicians in the appropriate treatment of SSTIs.


Complicated skin and skin structure infections (cSSTIs) account for almost 10 percent of all hospital admissions in the U.S.(1) According to the Centers for Disease Control and Prevention (CDC), approximately 25-30% of the U.S. population has some form of Staphylococcus aureus on their skin, and an increasing number of those individuals carry the more resistant form known as methicillin-resistant Staphylococcus aureus (MRSA).(2)(3)(4)

"Up to this point, the importance of initiating appropriate empiric* therapy has been well documented in other infections such as pneumonia, but not in skin infections," said study author Marcus Zervos, M.D. Division Head, Infectious Diseases, Director Infection Control at the Henry Ford Health System, in Detroit, MI. "These results show that a more comprehensive evaluation of hospital patient risk factors may help physicians determine the optimal initial antibiotic treatment, sparing patients unnecessary treatment and time in the hospital."

Risk Factors for Inappropriate Treatment

In the hospitalized patient population, three risk factors were identified as being associated with receiving inappropriate antibiotic treatment:

  • Healthcare-associated infection status (i.e., recent exposure within nursing homes, or medical clinics)
  • Presence of a "gram-negative" pathogen
  • Presence of a pathogen other than a Streptococcus species

Study Methods and Key Results

The study, conducted by the Henry Ford Health System with a grant from Ortho-McNeil Janssen Scientific Affairs, LLC, is an analysis of administrative and medical records of 368 patients hospitalized between late 2005 and 2008 with an admission diagnosis of a cSSTI. Patients were classified as having healthcare associated infections (HCAI) if they were: 1) recently hospitalized; 2) immunocompromised; 3) on hemodialysis; or 4) admitted from nursing home. All others were classified as having community-acquired infections (CAI). Initial empiric therapy (IET) was considered appropriate if antibiotics active against the infecting pathogen(s) were administered within 24 hours of admission.

Among patients with SSTIs whose infection was confirmed by culture ("culture-positive"), those who acquired an infection in a hospital or healthcare setting were more likely to be treated inappropriately than those who acquired an infection in a community setting (35.2% vs. 20.5%, p<0.01). Additionally, when other risk factors were adjusted, patients who received inappropriate initial therapy stayed in the hospital an average of nearly six days longer than patients who received appropriate initial therapy.

Moreover, the study showed that S. aureus was the most common pathogen in patients with both HCAI (55.6%) as well as CAI (58.2%), and the majority of these were methicillin-resistant S. aureus, commonly referred to as MRSA (73.4% in HCAI and 64.8% in CAI). MRSA represents a growing healthcare concern and has become an increasingly common cause of SSTIs, as evidenced by the prevalence of MRSA in this study.

Dr. Zervos is a principal investigator for the study and a paid consultant retained by Ortho-McNeil Janssen Scientific Affairs, LLC.

*Empiric treatment is defined as antibiotics prescribed prior to the identification of the causative pathogen(s) by culture results.

About Ortho-McNeil

Ortho-McNeil, Inc. is committed to providing innovative, high-quality prescription medicines, education and resources for patients, healthcare providers, and other members of the healthcare community in primary care, specialty and hospital settings. Based in Raritan, NJ, the company specializes in the areas of gastrointestinal and infectious diseases, pain management, women's health and urology, and has broad interest in other therapeutic categories. For more information, visit

(1) DiNubile MJ, Lipsky BA. Complicated Infections of skin and skin structures: when the infection is more than skin deep. JAC. 2004;53

(2) Halem M., et al. 2006. Community-acquired methicillin resistant Staphylococcus aureus skin infections. Semin. Cutan. Med. Surg. 25:68-71

(3) Kluytmans-Vandenbergh M.F., et al. 2006. Community-acquired methicillin resistant Staphylococcus aureus: current perspectives. Clin. Microbiol. Infect. 12 Suppl 1:9-15

(4) Kollef M.H., and S.T. Micek. 2006. Methicillin resistant Staphylococcus aureus: a new community acquired pathogen? Curr. Opin. Infect. Dis. 19:161-168

Media Contact: Amy Firsching, 908-218-7583

SOURCE Ortho-McNeil, Inc.

SOURCE Ortho-McNeil, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
2. Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
3. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE)
6. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
7. AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
8. EntreMed Presents Initial Clinical Results for ENMD-2076
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
11. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY ... products, continues to provide evidence demonstrating the accuracy of ... World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease ... that both the Company,s GLUCOCARD ® 01 meter ... high accuracy requirements. The ability to accurately measure glucose ...
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
(Date:11/26/2015)... ... ... PRMA Plastic Surgery is updating their record books yet again with an ... breast reconstruction surgery! , “What an accomplishment for the PRMA team, says Dr. ... an honor to have served all of these women.” , PRMA is one of ...
Breaking Medicine News(10 mins):